BioLineRx to Report Q3 2024 Financial Results on November 25 BLRX Stock News - StockTitan
| BLRX Stock | USD 3.56 0.01 0.28% |
Slightly above 64% of BioLineRx's investor base is looking to short. The analysis of the overall investor sentiment regarding BioLineRx suggests that many traders are alarmed. BioLineRx's investing sentiment can be driven by a variety of factors including economic data, BioLineRx's earnings reports, geopolitical events, and overall market trends.
BioLineRx |
BioLineRx to Report Q3 2024 Financial Results on November 25 BLRX Stock News StockTitan
Read at news.google.com
 |
BioLineRx Fundamental Analysis
We analyze BioLineRx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioLineRx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioLineRx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
BioLineRx is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
BioLineRx Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioLineRx stock to make a market-neutral strategy. Peer analysis of BioLineRx could also be used in its relative valuation, which is a method of valuing BioLineRx by comparing valuation metrics with similar companies.
Peers
BioLineRx Related Equities
| XFOR | X4 Pharmaceuticals | 6.06 | ||||
| APTO | Aptose Biosciences | 5.88 | ||||
| VRNA | Verona Pharma | 4.40 | ||||
| MREO | Mereo BioPharma | 2.73 | ||||
| CDTX | Cidara Therapeutics | 2.65 | ||||
| FBIO | Fortress Biotech | 2.25 | ||||
| PLX | Protalix Biotherapeutics | 2.10 | ||||
| ACHL | Achilles Therapeutics | 0.89 | ||||
| IBRX | Immunitybio | 0.58 | ||||
| INZY | Inozyme Pharma | 1.37 | ||||
| FBIOP | Fortress Biotech | 1.68 | ||||
| ARDX | Ardelyx | 2.19 | ||||
| MCRB | Seres Therapeutics | 2.33 | ||||
| ARQT | Arcutis Biotherapeutics | 3.15 | ||||
| TERN | Terns Pharmaceuticals | 3.88 | ||||
| LXRX | Lexicon Pharmaceuticals | 7.32 | ||||
| MBIO | Mustang Bio | 7.89 | ||||
| LPTX | Leap Therapeutics | 8.77 | ||||
| VRCA | Verrica Pharmaceuticals | 9.72 |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.